This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thiele, A. Articles by Hauschildt, S. Search for Related Content PubMed PubMed Citation Articles by Thiele, A. Articles by Hauschildt, S.

 Previous Article  |  Next Article 

Infection and Immunity, March 2004, p. 1349-1357, Vol. 72, No. 3
0019-9567/04/$08.00+0     DOI: 10.1128/IAI.72.3.1349-1357.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Regulation of Adenosine Receptor Subtypes during Cultivation of Human Monocytes: Role of Receptors in Preventing Lipopolysaccharide-Triggered Respiratory Burst

Andrea Thiele,^1, Romy Kronstein,^1, Anne Wetzel,^1, Anja Gerth,¹ Karen Nieber,² and Sunna Hauschildt^1*

Institute of Zoology, Department of Immunobiology,¹ Institute of Pharmacy, Department of Pharmacology for Natural Sciences, University of Leipzig, D-04103 Leipzig, Germany²

Received 13 June 2003/ Returned for modification 29 July 2003/ Accepted 10 December 2003

	ABSTRACT

Top Abstract Introduction Materials and Methods Results Discussion References

 
Adenosine is a potent anti-inflammatory agent that modulates the function of cells involved in the inflammatory response. Here we show that it inhibits lipopolysaccharide (LPS)-induced formation of reactive oxygen intermediates (ROI) in both freshly isolated and cultured human monocytes. Blocking of adenosine uptake and inactivation of the adenosine-degrading enzyme adenosine deaminase enhanced the inhibitory action of adenosine, indicating that both pathways regulate the extracellular adenosine concentration. Adenosine-mediated inhibition could be reversed by XAC (xanthine amine congener), an antagonist of the adenosine receptor A_2A, and MRS 1220 {N-9-chloro-2-(2-furanyl)[1, 2, 4]-triazolo[1,5-c]quinazolin-5-benzeneacetamide}, an A₃ receptor antagonist, in both cell populations, while DPCPX (1,3-dipropyl-8-cyclopentylxanthine), an A₁ receptor antagonist, had no effect. Similar to what was seen with adenosine, CGS 21680, an A_2A and A₃ receptor agonist, and IB-MECA, a nonselective A₁ and A₃ receptor agonist, dose dependently prevented ROI formation, indicating the involvement of A₃ and probably also A_2A in the suppressive effect of adenosine. Pretreatment of monocytes with adenosine did not lead to changes in the LPS-induced increase in intracellular calcium levels ([Ca²⁺]_i). Thus, participation of [Ca²⁺]_i in the action of adenosine seems unlikely. The adenosine-mediated suppression of ROI production was found to be more pronounced when monocytes were cultured for 18 h, a time point at which changes in the mRNA expression of adenosine receptors were observed. Most prominent was the increase in the A_2A receptor mRNA. These data demonstrate that cultivation of monocytes is accompanied by changes in the inhibitory action of adenosine mediated by A₃ and probably also the A_2A receptor and that regulation of adenosine receptors is an integral part of the monocyte differentiation program.

	INTRODUCTION

Top Abstract Introduction Materials and Methods Results Discussion References

 
Adenosine is a ubiquitous purine nucleoside that regulates a variety of physiologic processes through ligation of the four known adenosine receptors, designated A₁, A_2A, A_2B, and A₃ (13, 36, 38). The receptors have been cloned and the deduced sequences revealed that all four are members of the large family of seven transmembrane-spanning, G-protein-coupled receptors (35). A₁ and A₃ receptors inhibit adenyl cyclase, whereas A_2A and A_2B receptors activate the enzyme (41, 45). Furthermore, it was found that adenosine receptors can also couple to other second messenger systems, such as calcium or potassium channels (A₁) and phospholipase C (A₁, A_2B, and A₃) (38).

Recently, it was shown that adenosine, acting at one or more of its receptors, mediates the anti-inflammatory effects of drugs such as methotrexate, commonly used in the treatment of inflammation and chronic arthritis (5, 8).

During conditions associated with metabolic stress, such as ischemia, tissue injury, and inflammation, adenosine can be formed and released into the extracellular space as a result of a rapid degradation of intracellular ATP (10, 24, 30, 44). At these concentrations, adenosine modulates functional responses of inflammatory cells, including monocytes (31). By the occupancy of A₂ receptors, adenosine inhibits the production of tumor necrosis factor alpha and interleukin 12 (IL-12) (3, 17, 29, 37), whereas secretion of IL-10, a protective cytokine that suppresses release of IL-12 and tumor necrosis factor alpha, was found to be enhanced (16, 25). Besides diminishing cytokine production, adenosine exerts other anti-inflammatory effects, including inhibition of phagocytosis and C2 production (11, 23). Testing the ability of adenosine to inhibit phagocytosis by monocytes and macrophages, Eppell et al. (11) found that while adenosine had no effect on phagocytosis of freshly isolated monocytes, it acts as a powerful inhibitor in macrophages. According to their data, differentiation of monocytes to macrophages is accompanied by a dramatic increase of A₂ receptors, implying that inhibition of the phagocytic activity is regulated by A₂ receptors.

Another important biological response associated with inflammation is the release of reactive oxygen intermediates (ROI) by phagocytes. ROI, including hydrogen peroxide (H₂O₂), hydroxyl radical (OH^-), and hypochlorous acid (HOCl), are derived from O₂^-, which is produced in the so-called respiratory burst via an NADPH oxidase. By generating these toxic oxidants, phagocytes kill and degrade invading microorganisms. However, an uncontrolled production of ROI in various inflammatory conditions may result in pathological tissue injury (2, 19).

Whereas much attention has been paid to the inhibitory action of adenosine on the oxidative burst in neutrophils (6, 7, 9, 14, 42), little is known about its action in monocytes. Therefore, we tested the ability of adenosine to modulate lipopolysaccharide (LPS)-induced ROI production in human monocytes and studied the role of adenosine receptors involved in this process. Furthermore, we investigated whether differentiation of monocytes to macrophages is accompanied by changes in the inhibitory action of adenosine on ROI production and whether differentiation has any impact on the mRNA expression of the four adenosine receptor subtypes.

	MATERIALS AND METHODS

Top Abstract Introduction Materials and Methods Results Discussion References

 
Materials. LPS (Escherichia coli 055:B5), adenosine, N-9-chloro-2-(2-furanyl)[1, 2, 4]-triazolo[1,5-c]quinazolin-5-benzeneacetamide (MRS 1220), 2-p-(2-carboxyethyl)-phenethylamino-5-N-ethylcarboxamidoadenosine (CGS 21680), N6-(3-iodobenzyl)adenosine-5'-N-methyluron-amide (IB-MECA), 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), adenosine deaminase, dipyridamole, and erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) were obtained from Sigma-Aldrich Chemie GmbH (Steinheim, Germany). Xanthine amine congener (XAC) was obtained from ICN Biomedicals GmbH (Eschwege, Germany), and luminol was obtained from Roche (Basel, Switzerland). The oligonucleotides were synthesized by MWG Biotech AG (Ebersberg, Germany). The A_2A primers were a kind gift of B. N. Cronstein (New York University School of Medicine, New York, N.Y.).

Cell preparation. Monocytes were prepared from human blood or buffy coats by using Ficoll-Isopaque density gradient centrifugation (Pharmacia, Freiburg, Germany). After being washed in phosphate-buffered saline containing 0.3 mM EDTA, the monocytes were isolated by counterflow centrifugation using the J6-MC elutriator system (Beckman Instruments, Palo Alto, Calif.) as described previously (15). Fractions of 80 to 90% human monocytes were used. Monocytes (5 x 10⁵ cells/ml) were either used immediately after elutriation or incubated for 18 h or 7 days in RPMI 1640 containing 2% human AB serum, 1 mg of NaHCO₃/ml, 60 µM ß-mercaptoethanol, 4 mM L-glutamine (Seromed Biochrom KG, Berlin, Germany), 80 U of penicillin (Seromed Biochrom KG)/ml, 80 µg of streptomycin (Seromed Biochrom KG)/ml, 1 mM sodium pyruvate, nonessential amino acids (1%; Seromed Biochrom KG), and vitamin solution (0.4%; Gibco BRL, Eggstein, Germany) in 6-well plates (TPP, Trasadingen, Switzerland) at 37°C in an atmosphere of 5% CO₂.

Measurement of intracellular calcium levels ([Ca²⁺]_i) by Ca²⁺ imaging. A sample (300 µl) of cell suspension (2 x 10⁶/ml) was seeded onto 30-mm-diameter sterile glass coverslips (Marienfeld Laboratory, Bad Mergentheim, Germany) incubated for 30 min at 37°C in an atmosphere of 5% CO₂. Monocytes that adhered to coverslips were incubated with 10 µM 1-[2-(5-carboxyoxazol-2-yl)-6-aminobenzofuran-5-oxy]-2-(2'-amino-5'-methylphenoxy)ethane-N,N,N',N'-tetraacetic acid pentaacetoxymethyl ester (FURA-2/AM) (TEF Labs, Austin, Tex.) and 0.0125% Pluronic F-127 (TEF Labs) in 1 ml of standard Ca²⁺ solution at room temperature for 30 min in the dark.

The standard solution contained 125 mM NaCl, 5 mM KCl, 2 mM CaCl₂, 10 mM HEPES, and 7.5 mM glucose (adjusted to pH 7.4 with NaOH). The zero calcium solution contained 125 mM NaCl, 5 mM KCl, 2 mM MgCl₂ · 6 H₂O, 1 mM EGTA, 10 mM HEPES, and 7.5 mM glucose (adjusted to pH 7.4 with NaOH). The coverslips were placed in a recording chamber and continuously perfused at room temperature at a rate of 2 ml/min. Solutions were removed by a vacuum pump.

Experiments were performed on a microscope (Axiovert 135; Carl Zeiss Jena GmbH, Jena, Germany) equipped with UV transparent optics (Axiovert 135). Dye excitation illumination was provided by a dual-wavelength illuminator system (T.I.L.L. Photonics GmbH, Gräfelfing, Germany) consisting of a xenon arc lamp, a variable-speed reflective optic chopper, and two monochromators, both under computer control. The excitation and emission wavelengths used were 340 and 380 nm, respectively. Emitted fluorescence filtered at 510 nm was collected by a photomultiplier tube and photon-counting photometer. Changes in [Ca²⁺]_i were expressed as the ratio of dye fluorescence at 340 nm to that at 380 nm. Calcium measurements were performed on fields containing 45 to 70 cell bodies.

Luminol-amplified chemiluminescence assay. Chemiluminescence assays were performed at 37°C using a MicroLumat 96P luminometer (Berthold, Bad Wildbad, Germany). Monocytes (1.6 x 10⁶/ml) were suspended in RPMI 1640 (without phenol red) supplemented with 1% fetal calf serum and 5 mM HEPES (Seromed Biochrom KG, Berlin, Germany). The cells were allowed to equilibrate at 37°C and 5% CO₂ for 30 min in white polystyrene 96 microtiter plates (Wallac, Turku, Finland) in the presence of 140 µM luminol in a final volume of 250 µl. Then the plates were transferred to the luminometer and background readings were recorded. After 30 min, the agonist, the antagonist, or, with a latency of 5 min, both the antagonist and then the agonist were added to the cells and incubation continued for an additional 30 min before LPS (100 ng/ml) was added. The readings continued for a further 120 min.

All data are based on the calculation of the area under the curve by using the Winglow 1.02 program (Berthold). Percentage inhibition was calculated in relation to the control. Luminol-dependent chemiluminescence (LDCL) is given in terms of relative light units per second.

Semiquantitative reverse transcription-PCR. Total RNA was isolated from 6 x 10⁶ cells by using an RNeasy mini kit (Qiagen, Chatsworth, Calif.) according to the manufacturer's instructions. cDNA was prepared by annealing RNA with oligo(dT)₂₀ for 10 min at 70°C and reverse transcription using SuperScript II reverse transcriptase (Life Technologies, Gaithersburg, Md.) at 37°C for 60 min, followed by an inactivation phase of 4 min at 94°C.

An aliquot of each reverse transcription sample was added to the reaction mixture containing 1.5 mM MgCl₂, 200 µM deoxynucleoside triphosphate, and 1 µM concentrations of both the sense and antisense primers and 30 U of Taq DNA polymerase (Life Technologies)/ml.

The primers used in the PCR were as follows: for the A₁ receptor cDNA, sense primer 5'-CAC CTT CTG CTT CAT CGT GTC and antisense primer 5'-AGC CAA ACA TAG GGG TCA GTC; for the A_2A receptor cDNA, sense primer 5'-ACC TGC AGA AGC TCA CCA AC and antisense primer 5'-TCT GCT TCA GCT GTC GTC GC; for the A_2B receptor cDNA, sense primer 5'-GCC ATG CTG CTG GAG ACA CAG and antisense primer 5'-CTG GAG GGT GGT CCT CGA GTG; for the A₃ receptor cDNA, (4), sense primer 5'-GCT TAT CTT TAC CCA CGC CTC C and antisense primer 5'-CCG TCT TGA ACT CCC GTC CAT A; and for the GAPDH cDNA, sense primer 5'-AAC AGC GAC ACC CAC TCC TC and antisense primer 5'-GGA GGG GAG ATT CAG TGT GGT. All primer pairs used were intron spanning.

Reactions were performed in a Crocodile III DNA thermal cycler (Oncor Appligene, Heidelberg, Germany) under the following conditions: an initial denaturation step for 5 min at 95°C followed by cycles of 60 s at 95°C, 60 s at 65°C (A₁), 62°C (A_2A), 68°C (A_2B and A₃), or 60°C (GAPDH), and 90 s at 72°C, with a prolongation of 2 s per cycle. The final extension phase was 5 min at 72°C. The numbers of cycles were 35 for A₁; 30 for A_2A, A_2B, and A₃; and 20 for GAPDH. The PCR products were separated by electrophoresis on 1.8% agarose gels (FMC Bioproducts, Rockland, Mass.) containing 1 µg of ethidium bromide/ml and visualized under UV light. The 100-bp ladder (Life Technologies) served as a molecular weight standard. The amounts of GAPDH PCR product were used as a reference.

Statistics. Each experiment was performed in duplicate. The WinGlow 1.02 program (Berthold) was used for data analysis. Data are presented as means ± standard errors of the means (SEM) of three independent experiments. Multiple comparisons with a control value were performed by one-way analysis of variance followed by Bonferroni's t test. All other comparisons were made by paired Student's t test. A probability level of 0.05 or less was considered to be statistically significant. The concentration-response curves were confirmed by a nonlinear regression. The 50% inhibitory concentrations (IC₅₀s) were calculated from the concentration-response curves.

	RESULTS

Top Abstract Introduction Materials and Methods Results Discussion References

 
Adenosine inhibits LPS-induced ROI production in freshly isolated and cultured human monocytes. Treatment of freshly isolated monocytes with LPS (100 ng/ml) led to a rapid production of ROI (Fig. 1). In the absence of LPS, no ROI were produced. When the monocytes were preincubated with adenosine (1, 10, 50, 100, and 200 µM), LPS-triggered ROI production was suppressed in a concentration-dependent manner (IC₅₀ 33.6 µM) (Fig. 2). The course of the concentration-response curve was similar when cultured monocytes were used (IC₅₀ 8.5 µM) (Fig. 2). A cultivation time of 18 h was chosen because at later time points monocytes cease to produce ROI in response to LPS (27, 33, 43, 46). At an adenosine concentration of 200 µM, ROI production in freshly isolated and cultured monocytes was inhibited by 41.1% ± 3.6% (n = 3) and 44.3% ± 4% (n = 3), respectively.

View larger version (28K): [in this window] [in a new window]   FIG. 1. Concentration-response curves showing the effect of adenosine on LPS-induced ROI production in freshly isolated monocytes. ROI production was determined by LDCL as described in Materials and Methods. Freshly isolated monocytes (1.6 x 106/ml) were incubated in the presence of adenosine for 30 min before LPS (100 ng/ml) was added. A representative recording of three different experiments is shown. RLU, relative light units.

View larger version (14K): [in this window] [in a new window]   FIG. 2. Concentration-response curves showing the effect of adenosine on LPS-induced ROI production in freshly isolated and cultured monocytes. ROI production was determined by LDCL as described in Materials and Methods. Freshly isolated and cultured monocytes (1.6 x 106/ml) were incubated in the presence of adenosine for 30 min before LPS (100 ng/ml) was added. All data are expressed as percentages of the LPS (100 ng/ml)-induced ROI formation (100%). Each point represents the mean ± SEM of three independent experiments.

View larger version (13K): [in this window] [in a new window]   FIG.3. Effect of adenosine deaminase, EHNA, inosine, and dipyridamole on LPS-induced and adenosine-mediated inhibition of ROI production. ROI production was determined by LDCL as described in Materials and Methods. (A) Freshly isolated monocytes (1.6 x 106/ml) were incubated either in the presence or absence of adenosine deaminase (0.25 U/ml) or EHNA (5 µM) for 5 min prior to the addition of adenosine (100 µM), and LPS (100 ng/ml) was added after 30 min. All data are expressed as percentages of the LPS (100 ng/ml)-induced ROI formation (100%). Data represent the means ± SEM of two to three independent experiments. (B) Freshly isolated and cultured monocytes (1.6 x 106/ml) were incubated with different concentrations of inosine for 30 min prior to the addition of LPS (100 ng/ml). All data are expressed as percentages of the LPS (100 ng/ml)-induced ROI formation (100%). Each point represents the mean ± SEM of three independent experiments. (C) Freshly isolated and cultured monocytes (1.6 x 106/ml) were incubated with 0, 0.1, 1, or 10 µM dipyridamole for 5 min prior to the addition of different concentrations of adenosine, and LPS (100 ng/ml) was added after 30 min. All data are expressed as percentages of the LPS (100 ng/ml)-induced ROI formation (100%). Each point represents the mean ± SEM of three independent experiments.

To test whether cellular uptake of adenosine by monocytes influences the inhibitory effect on ROI production, the cells were treated with dipyridamole (0.1, 1, and 10 µM) prior to the addition of adenosine (10, 100, and 200 µM) and LPS (100 ng/ml). As shown in Fig. 3C, dipyridamole by itself inhibited the ROI production in a concentration-dependent manner. Addition of adenosine potentiated this inhibitory effect.

Analysis of adenosine receptor subtype mRNA expression in freshly isolated and cultured human monocytes and in macrophages. The inhibitory action of adenosine on the LPS-induced oxidative burst and the potentiation of this effect when the adenosine uptake is blocked imply the involvement of adenosine receptor subtypes. Before identifying the receptor(s) mediating the action, we determined which of the four receptor mRNAs were present in monocytes and whether they were regulated during cultivation. The expression of the A_2A and A_2B receptor mRNA was far less pronounced in freshly isolated than in cells cultured for 18 h (Fig. 4). After 7 days in culture, A_2B receptor mRNA expression hardly changed whereas A_2A receptor mRNA was no longer detectable. The kinetics of the A₁ and A₃ receptor mRNA expression showed a slight increase after 7 days of culture.

View larger version (32K): [in this window] [in a new window]   FIG. 4. Adenosine receptor subtype mRNA expression in freshly isolated and cultured human monocytes. cDNAs of freshly isolated monocytes and monocytes cultured for 18 h and 7 days were prepared. Semiquantitative PCR was performed with specific primers for A1, A2A, A2B, and A3 adenosine receptors and GAPDH. The amounts of GAPDH PCR products were used as a reference for semiquantitative analysis. As a negative control, water was used in the PCR. The 100-bp ladder was used as a DNA size marker. One representative experiment out of three is shown.

View larger version (15K): [in this window] [in a new window]   FIG. 5. Effects of adenosine and adenosine receptor antagonists on LPS-induced ROI production in freshly isolated and cultured monocytes. ROI production was determined by LDCL as described in Materials and Methods. Freshly isolated and cultured monocytes (1.6 x 106/ml) were preincubated with the respective adenosine antagonists for 5 min before adenosine was added. After 30 min of incubation, cells were stimulated with LPS (100 mg/ml). The antagonists used to block the adenosine receptor subtypes were DPCPX, XAC, and MRS 1220. All data are expressed as percentages of the LPS (100 ng/ml)-induced ROI production (100%). Data represent the means ± SEM of three independent experiments. *, P < 0.05 (significant difference compared to the LPS-induced ROI production); , P < 0.05 (significant difference compared to the adenosine-induced inhibition of ROI production).

View larger version (11K): [in this window] [in a new window]   FIG. 6. (A) Concentration-response curves showing the effect of the A2A and A3 receptor agonist CGS 21680 on LPS-induced ROI production in freshly isolated and cultured monocytes. ROI production was determined by LDCL as described in Materials and Methods. Freshly isolated monocytes and cultured monocytes (1.6 x 106/ml) were incubated with CGS 21680 (1 to 50 µM) for 30 min before addition of LPS (100 mg/ml). Data represent the means ± SEM of three independent experiments. (B) Effect of adenosine antagonists on CGS 21680-mediated inhibition of LPS-induced ROI production. ROI production was determined by LDCL as described in Materials and Methods. Freshly isolated monocytes (1.6 x 106/ml) were incubated with 1 µM concentrations of the antagonist DPCPX, XAC, or MRS 1220 for 5 min before CGS 21680 (50 µM) was added. After 30 min of incubation, the cells were stimulated with LPS (100 mg/ml). All data are expressed as percentages of the LPS (100 ng/ml)-induced ROI production (100%). Each point represents the mean ± SEM of three independent experiments.

Compared to CGS 21680, IB-MECA suppressed the LPS-induced ROI production more efficiently (Fig. 7A). At a concentration of only 10 µM, inhibitions in freshly isolated and cultured monocytes were found to be 45 and 67%, respectively. The inhibitory effect of IB-MECA could be prevented by XAC, whereas MRS 1220 partly reversed the inhibition and DPCPX had no effect (Fig. 7B).

View larger version (12K): [in this window] [in a new window]   FIG. 7. (A) Concentration-response curves showing the effect of the A1 and A3 receptor agonist IB-MECA on LPS-induced ROI production in freshly isolated and cultured monocytes. ROI production was determined by LDCL as described in Materials and Methods. Freshly isolated monocytes and cultured monocytes (1.6 x 106/ml) were incubated with IB-MECA (1 to 50 µM) for 30 min before addition of LPS (100 mg/ml). Each point represents the mean ± SEM of three independent experiments. (B) Effect of adenosine antagonists on IB-MECA-mediated inhibition of LPS-induced ROI production. ROI production was determined by LDCL as described in Materials and Methods. Freshly isolated monocytes (1.6 x 106/ml) were incubated with a 1 µM concentration of the antagonist DPCPX, XAC, or MRS 1220 for 5 min before IB-MECA (10 µM) was added. After 30 min of incubation, the cells were stimulated with LPS (100 mg/ml). All data are expressed as percentages of the LPS (100 ng/ml)-induced ROI production (100%). Data represent the means ± SEM of three independent experiments. *, P < 0.05 (significant difference compared to the LPS-induced ROI production); , P < 0.05 (significant difference compared to the IB-MECA-induced inhibition of ROI production).

View larger version (14K): [in this window] [in a new window]   FIG. 8. Effect of adenosine on LPS-induced increase in [Ca2+]i. (A) Monocytes were treated with standard solution (shaded bar) prior to the application of LPS (100 ng/ml) (white bar, solid line) or standard solution (white bar, broken line). [Ca2+]i was measured as the ratio of the 340-nm emission line to the 380-nm emission line. Shown are representative traces from one of three experiments. (B) Monocytes were treated with adenosine (200 µM) (shaded bar) prior to the application of LPS (100 ng/ml) (white bar, solid line) or standard solution (white bar, broken line). [Ca2+]i was measured as the ratio of the 340-nm emission line to the 380-nm emission line. Shown are representative traces from one of three experiments. The number of cells responding to adenosine was 33 of 65 (51%) (panel B, broken line) or 45 of 75 (60%) (panel B, solid line).

	DISCUSSION

Top Abstract Introduction Materials and Methods Results Discussion References

When studying the involvement of the adenosine receptors in mediating the adenosine-induced inhibition of ROI production, relatively high concentrations (micromolar) of adenosine were needed to exert an effect. This is in line with data from other reports in which the inhibitory action of adenosine on ROI production and other biological answers in monocytes have been described (3, 4, 17, 26, 40). According to our data, the IC₅₀s may result from a rapid uptake and an extensive metabolism of adenosine.

We found that the blockade of adenosine uptake (by dipyridamole) and the inhibition of endogenous adenosine deaminase activity (by EHNA) both resulted in a decrease in LPS-induced ROI production even in the absence of exogenous adenosine, indicating that endogenous adenosine is produced in stimulated monocytes and that adenosine, if spared from uptake and degradation, exerts its inhibitory effects by acting at its receptors. To our surprise, the addition of adenosine deaminase to the cells in the absence or presence of adenosine did not result in an increase in ROI production. The fact that inhibition of adenosine deaminase by EHNA caused a drastic inhibition of the oxidative burst points to high adenosine deaminase activity so that further addition of adenosine deaminase may not affect the equilibrium between adenosine and adenosine deaminase in the cell culture.

A₃ (monocytes) and A_2A and probably A₃ (neutrophils) have mainly been suggested to be the adenosine receptor subtypes that mediate the inhibitory action of adenosine on fMLP (formyl-Met-Leu-Phe)-induced respiratory burst in monocytes (4) and neutrophils (9, 14). In line with these observations, our data indicate that the action of adenosine on LPS-induced ROI production depends on A₃ and probably also A_2A activation. This conclusion is based on the observation that the A_2A and A₃ antagonists XAC and MRS 1220 blocked the inhibitory action of adenosine while the A₁ antagonist DPCPX was without effect.

In humans, XAC has been described as A_2A selective (K_i 1 nM) (22), with the K_i for A₃ being 92 nM (22), and MRS 1220 has been described as A₃ selective (K_i 0.65 nM) (21), with the K_i for A_2A being 15 nM (32). It should be pointed out that at a concentration of 1 µM, as used in this study, both antagonists can block both receptor subtypes. Lowering the concentration of XAC and MRS 1220 to 10 nM, a concentration at which MRS 1220 might bind only to A₃ and XAC only to A_2A did not prevent the inhibition induced by adenosine (100 µM), IB-MECA (10 µM), or CGS 21680 (50 µM) (data not shown). This might be due to the fact that the concentration of the antagonists is 10,000 to 1,000 times lower than that of the agonists.

Irrespective of these limitations, IB-MECA, a nonselective A₁ and A₃ receptor agonist (22), and CGS 21680, which shows some degree of selectivity for A_2A receptors (22), were tested for their ability to block LPS-induced ROI production. Both agonists dose dependently inhibited ROI formation, with IB-MECA being more effective than CGS 21680. Similar to adenosine, IB-MECA and CGS 21680 exerted their effects only at concentrations in the micromolar range. The presence of adenosine deaminase had no influence on their inhibitory action (data not shown). As the enzyme did not prevent the inhibitory action of exogenous adenosine, it is possible that due to the endogenous enzyme activity the adenosine concentration is too low to be responsible for the low affinity of the agonist. However, despite its relatively low affinity to the adenosine receptor, IB-MECA induced a complete inhibition of LPS-induced ROI production while adenosine only partly prevented ROI production. It is most likely that adenosine, in contrast to IB-MECA, is metabolized by adenosine deaminase or that adenosine binds to several receptors whereas IB-MECA is more selective.

As IB-MECA is more efficient than CGS 21680 in inhibiting the LPS-induced respiratory burst, an involvement of A₃ seems more likely than that of A_2A. However, the fact that inhibition induced by CGS 21680 and IB-MECA were both prevented by XAC, only partly blocked by MRS 1220, but not prevented by DPCPX supports an involvement of A_2A and A₃. The ability of XAC to prevent the effects of both CGS 21680 and IB-MECA suggests that this antagonist at a concentration of 1 µM blocked not only A_2A but also A₃.

It should be pointed out that the interpretation of the present data is based on K_i and K_d values of agonists and antagonists obtained from binding studies mainly carried out with transfected cell lines or isolated membrane preparations. In view of the tissue-specific differences in pharmacological properties, binding data for ligands may differ from functional data derived from experiments carried out with intact cells.

Comparing the inhibitory effects of A_2A and A₃ receptor agonists on freshly isolated monocytes with those on cultured monocytes clearly showed that the inhibitory action was stronger in the latter. Whether this is mirrored by an upregulation of the two receptors at the protein level remains to be clarified; an upregulation of the A_2A receptor mRNA, however, could be observed.

The intracellular mechanisms involved in the inhibition of ROI production by adenosine have yet to be defined. A previous study by Broussas et al. (4) indicated that signaling pathways in monocytes do not include adenylate cyclase-dependent cyclic AMP (cAMP) elevation or changes in calcium mobilization.

According to our results and in line with those of Broussas et al. (4), a signaling role of calcium seems unlikely since the application of adenosine failed to inhibit the LPS-induced rise in [Ca²⁺]_i. However, in contrast to Broussas et al., we found an increase in [Ca²⁺]_i upon addition of adenosine to monocytes. The percentage of cells that responded to adenosine varied among donors but monocytes from nearly all donors (12 of 15) did react. Nevertheless, the rise in [Ca²⁺]_i induced by LPS was not affected by adenosine. Thus, if calcium signaling is a prerequisite for LPS to activate the NADPH oxidase, the adenosine-mediated rise in [Ca²⁺]_i obviously does not affect signaling pathways that interfere with LPS-induced calcium signaling.

While Sullivan et al. (42) suggested an involvement of cAMP in A₂ receptor-mediated regulation of the oxidative burst in human neutrophils, other groups have questioned an enhancement of cAMP as an effector mechanism in these cells (6, 7). Alternative signal transduction mechanisms such as activation of a serine/threonine protein phosphatase (39) or participation of inositol 1,4,5-phosphate (IP3) in A₂ receptor-mediated events (34) have been proposed.

In summary, our data show that differentiation of monocytes to macrophages is accompanied by the differential expression of adenosine receptor mRNA. This may provide potential means to regulate adenosine-mediated biological answers. Differences in the adenosine-mediated inhibition of the LPS-induced oxidative burst were seen between cultivated and freshly isolated monocytes. How far this effect, which we showed to be mediated by A₃ and A_2A receptors, relates to the expression of the corresponding adenosine receptor protein remains to be clarified.

	ACKNOWLEDGMENTS

 
This work was supported by the Deutsche Forschungsgemeinschaft (INK 23/B7).

We thank B. N. Cronstein (New York University School of Medicine) for providing us with A_2A primers and for critical review of the manuscript and G. Baumbach for excellent technical assistance.

	FOOTNOTES

 
* Corresponding author. Mailing address: Institute of Zoology, Department of Immunobiology, University of Leipzig, Bruederstrasse 32, D-04103 Leipzig, Germany. Phone: 49 341-9736747. Fax: 49 341-9736848. E-mail: shaus{at}rz.uni-leipzig.de.

Editor: S. H. E. Kaufmann

Present address: Hubrecht Laboratorium for Developmental Biology, NL-3584 CT Utrecht, The Netherlands.

Present address: Institute of Physiology, Medical Faculty, Technical University Dresden, D-01307 Dresden, Germany.

Present address: Department of Dermatology, University Hospital Leipzig, D-04103 Leipzig, Germany.

	REFERENCES

Top Abstract Introduction Materials and Methods Results Discussion References

 

1.	Aran, J. M., D. Colomer, E. Matutes, J. L. Vives-Corrons, and R. Franco. 1991. Presence of adenosine deaminase on the surface of mononuclear blood cells: immunochemical localizations using light and electron microscopy. J. Histochem. Cytochem. 39:1001-1008.[Abstract]
2.	Bone, R. C. 1991. The pathogenesis of sepsis. Ann. Intern. Med. 115:457-469.
3.	Bouma, M. G., R. K. Stad, F. A. van den Wildenberg, and W. A. Buurman. 1994. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J. Immunol. 153:4159-4168.[Abstract]
4.	Broussas, M., P. Cornillet-Lefebvre, G. Potron, and P. Nguyen. 1999. Inhibition of fMLP-triggered respiratory burst of human monocytes by adenosine: involvement of A3 adenosine receptor. J. Leukoc. Biol. 66:495-501.[Abstract]
5.	Cronstein, B. N., and E. S. L. Chan. 2000. The mechanism of methotrexate's action in the treatment of inflammatory disease, p. 65-82. In B. N. Cronstein and J. R. Bertino (ed.), Methotrexate. Birkhäuser, Basel, Switzerland.
6.	Cronstein, B. N., K. A. Haines, S. L. Kolasinski, and J. Reibman. 1992. Occupancy of G alpha s-linked receptors uncouples chemoattractant receptors from their stimulus-transduction mechanisms in the neutrophil. Blood 80:1052-1057.[Abstract/Free Full Text]
7.	Cronstein, B. N., S. B. Kramer, E. D. Rosenstein, H. M. Korchak, G. Weissmann, and R. Hirschhorn. 1988. Occupancy of adenosine receptors raises cyclic AMP alone and in synergy with occupancy of chemoattractant receptors and inhibits membrane depolarization. Biochem. J. 252:709-715.[Medline]
8.	Cronstein, B. N., D. Naime, and E. Ostad. 1993. The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Investig. 92:2675-2682.
9.	Cronstein, B. N., E. D. Rosenstein, S. B. Kramer, G. Weissmann, and R. Hirschhorn. 1985. Adenosine: a physiologic modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils. J. Immunol. 135:1366-1371.[Abstract]
10.	Deussen, A. 2000. Metabolic flux rates of adenosine in the heart. Naunyn-Schmiedeberg's Arch. Pharmacol. 362:351-363.[CrossRef][Medline]
11.	Eppell, B. A., A. M. Newell, and E. J. Brown. 1989. Adenosine receptors are expressed during differentiation of monocytes to macrophages in vitro. J. Immunol. 143:4141-4145.[Abstract]
12.	Fischer, D., M. B. van der Weyden, R. Snydermann, and W. N. Kelley. 1976. A role for adenosine deaminase in human monocyte maturation. J. Clin. Investig. 58:399-407.
13.	Fredholm, B. B., A. P. Ijzerman, K. A. Jacobson, K. N. Klotz, and J. Linden. 2001. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53:527-552.[Abstract/Free Full Text]
14.	Gessi, S., K. Varani, S. Merighi, E. Cattabriga, V. Iannotta, E. Leung, P. G. Baraldi, and P. A. Borea. 2002. A3 adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study. Mol. Pharmacol. 61:415-424.[Abstract/Free Full Text]
15.	Grage-Griebenow, E., D. Lorenzen, R. Fetting, H. D. Flad, and M. Ernst. 1993. Phenotypical and functional characterization of Fc receptor I (CD64)-negative monocytes, a minor human monocyte subpopulation with high accessory and antiviral activity. Eur. J. Immunol. 23:3126-3135.[Medline]
16.	Haskó, G., C. Szabo, Z. H. Németh, V. Kvetan, S. M. Pastores, and E. S. Vizi. 1996. Adenosine receptor agonists differentially regulate IL-10, TNF-, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J. Immunol. 157:4634-4640.[Abstract]
17.	Haskó, G., D. G. Kuhel, J. F. Chen, M. A. Schwarzschild, E. A. Deitch, J. G. Mabley, A. Marton, and C. Szabo. 2000. Adenosine inhibits IL-12 and TNF- production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J. 14:2065-2074.[Abstract/Free Full Text]
18.	Haskó G., D. G. Kuhel, Z. H. Németh, J. G. Mabley, R. F. Stachlewitz, L. Virág, Z. Lohinai, G. J. Southan, A. L. Salzman, and C. Szabó. 2000. Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock. J. Immunol. 164:1013-1019.[Abstract/Free Full Text]
19.	Henson, P. M., and R. B. Johnston, Jr. 1987. Tissue injury in inflammation: oxidants, proteinases, and cationic proteins. J. Clin. Investig. 79:669-674.
20.	Ji, X. D., and K. A. Jacobson. 1999. Use of the triazolotriazine [3H]ZM 241385 as a radioligand at recombinant human A2B adenosine receptors. Drug Design Discov. 16:217-226.[Medline]
21.	Kim, Y. C., X. D. Ji, and K. A. Jacobson. 1996. Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype. J. Med. Chem. 39:4142-4148.[CrossRef][Medline]
22.	Klotz, K. N., J. Hessling, J. Hegler, C. Owman, B. Kull, B. B. Fredholm, and M. J. Lohse. 1998. Comparative pharmacology of human adenosine receptor subtypes: characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's Arch. Pharmacol. 357:1-9.[Medline]
23.	Lappin, D., and K. Whaley. 1984. Adenosine A2 receptors on human monocytes modulate C2 production. Clin. Exp. Immunol. 57:454-460.[Medline]
24.	Latini, S., F. Bordoni, F. Pedata, and R. Corradetti. 1999. Extracellular adenosine concentrations during in vitro ischaemia in rat hippocampal slices. Br. J. Pharmacol. 127:729-739.[CrossRef][Medline]
25.	Le Moine, O., P. Stordeur, L. Schandené, A. Marchant, D. de Groote, M. Goldman, and J. Deviere. 1996. Adenosine enhances IL-10 secretion by human monocytes. J. Immunol. 156:4408-4414.[Abstract]
26.	Leonard, E. J., A. Shenai, and A. Skeel. 1987. Dynamics of chemotactic peptide-induced superoxide generation by human monocytes. Inflammation 11:229-240.[CrossRef][Medline]
27.	Levy, R., and H. L. Malech. 1991. Effect of 1,25-dihydroxyvitamin D3, lipopolysaccharide, or lipoteichoic acid on the expression of NADPH oxidase components in cultured human monocytes. J. Immunol. 147:3066-3071.[Abstract]
28.	Linden, J., T. Thai, H. Figler, X. Jin, and A. S. Robeva. 1999. Characterization of human A(2B) adenosine receptors: radioligand binding, Western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells. Mol. Pharmacol. 56:705-713.[Abstract/Free Full Text]
29.	Link, A. A., T. Kino, J. A. Worth, J. L. McGuire, M. L. Crane, G. P. Chrousos, R. L. Wilder, and I. J. Elenkov. 2000. Ligand-activation of the adenosine A2A receptors inhibits IL-12 production by human monocytes. J. Immunol. 164:436-442.[Abstract/Free Full Text]
30.	Matherne, G. P., J. P. Headrick, S. D. Coleman, and R. M. Berne. 1990. Interstitial transudate purines in normoxic and hypoxic immature and mature rabbit hearts. Pediatr. Res. 28:348-353.[Medline]
31.	Montesinos, M. C., and B. N. Cronstein. 2001. Role of P1 receptors in inflammation, p. 303-321. In M. P. Abbracchio and M. Williams (ed.), Handbook of experimental pharmacology. Purinergic and pyrimidinergic signalling, vol 2. Springer Verlag, Berlin, Germany.
32.	Murphree, L. J., M. A. Marshall, J. M. Rieger, T. L. MacDonald, and J. Linden. 2002. Human A(2A) adenosine receptors: high-affinity agonist binding to receptor-G protein complexes containing Gß(4). Mol. Pharmacol. 61:455-462.[Abstract/Free Full Text]
33.	Nakagawara, A., C. F. Nathan, and Z. A. Cohn. 1981. Hydrogen peroxide metabolism in human monocytes during differentiation in vitro. J. Clin. Investig. 68:1243-1252.
34.	Offermanns, S., and M. I. Simon. 1995. G15 and G16 couple a wide variety of receptors to phospholipase C. J. Biol. Chem. 270:15175-15180.[Abstract/Free Full Text]
35.	Olah, M. E., and G. L. Stiles. 1995. Adenosine receptor subtypes: characterization and therapeutic regulation. Annu. Rev. Pharmacol. Toxicol. 35:581-606.[CrossRef][Medline]
36.	Palmer, T. M., and G. L. Stiles. 1995. Adenosine receptors. Neuropharmacology 34:683-694.[CrossRef][Medline]
37.	Prabhakar, U., D. P. Brooks, D. Lipshlitz, and K. M. Esser. 1995. Inhibition of LPS-induced TNF- production in human monocytes by adenosine (A2) receptor selective agonists. Int. J. Immunopharmacol. 17:221-224.[CrossRef][Medline]
38.	Ralevic, V., and G. Burnstock. 1998. Receptors for purines and pyrimidines. Pharmacol. Rev. 50:413-492.[Abstract/Free Full Text]
39.	Revan, S., M. C. Montesinos, D. Naime, S. Landau, and B. N. Cronstein. 1996. Adenosine A2 receptors occupancy regulates stimulated neutrophil function via activation of a serine/threonine protein phosphatase. J. Biol. Chem. 271:17114-17118.[Abstract/Free Full Text]
40.	Si, Q. S., Y. Nakamura, and K. Kataoka. 1997. Adenosine inhibits superoxide production in rat peritoneal macrophages via elevation of cAMP level. Immunopharmacology 36:1-7.[CrossRef][Medline]
41.	Stiles, G. L. 1992. Adenosine receptors. J. Biol. Chem. 267:6451-6454.[Abstract/Free Full Text]
42.	Sullivan G. W., J. M. Rieger, W. W. Scheld, T. L. Macdonald, and J. Linden. 2001. Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists. Br. J. Pharmacol. 132:1017-1026.[CrossRef][Medline]
43.	Turpin, J., E. M. Hersh, and G. Lopez-Berestein. 1986. Characterization of small and large human peripheral blood monocytes: effects of in vitro maturation on hydrogen peroxide release and on the response to macrophage activators. J. Immunol. 136:4194-4198.[Abstract]
44.	Van Belle, H., F. Goossens, and J. Wynants. 1987. Formation and release of purine catabolites during hypoperfusion, anoxia, and ischemia. Am. J. Physiol. 252:H886-H893.
45.	van Calker, D., M. Muller, and B. Hamprecht. 1979. Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J. Neurochem. 33:999-1005.[Medline]
46.	Zeller, J. M., J. Caliendo, T. F. Lint, and D. J. Nelson. 1988. Changes in respiratory burst activity during human monocyte differentiation in suspension culture. Inflammation 12:585-595.[CrossRef][Medline]

This article has been cited by other articles:

• Auchampach, J. A. (2007). Adenosine Receptors and Angiogenesis. Circ. Res. 101: 1075-1077 [Full Text]  
• Clark, A. N., Youkey, R., Liu, X., Jia, L., Blatt, R., Day, Y.-J., Sullivan, G. W., Linden, J., Tucker, A. L. (2007). A1 Adenosine Receptor Activation Promotes Angiogenesis and Release of VEGF From Monocytes. Circ. Res. 101: 1130-1138 [Abstract] [Full Text]  
• Ernens, I., Rouy, D., Velot, E., Devaux, Y., Wagner, D. R. (2006). Adenosine Inhibits Matrix Metalloproteinase-9 Secretion By Neutrophils: Implication of A2a Receptor and cAMP/PKA/Ca2+ Pathway. Circ. Res. 99: 590-597 [Abstract] [Full Text]  
• Fortin, A., Harbour, D., Fernandes, M., Borgeat, P., Bourgoin, S. (2006). Differential expression of adenosine receptors in human neutrophils: up-regulation by specific Th1 cytokines and lipopolysaccharide. J. Leukoc. Biol. 79: 574-585 [Abstract] [Full Text]  
• Martin, L., Pingle, S. C., Hallam, D. M., Rybak, L. P., Ramkumar, V. (2006). Activation of the Adenosine A3 Receptor in RAW 264.7 Cells Inhibits Lipopolysaccharide-Stimulated Tumor Necrosis Factor-{alpha} Release by Reducing Calcium-Dependent Activation of Nuclear Factor-{kappa}B and Extracellular Signal-Regulated Kinase 1/2. J. Pharmacol. Exp. Ther. 316: 71-78 [Abstract] [Full Text]  
• Gessi, S., Varani, K., Merighi, S., Cattabriga, E., Pancaldi, C., Szabadkai, Y., Rizzuto, R., Klotz, K.-N., Leung, E., Mac Lennan, S., Baraldi, P. G., Borea, P. A. (2005). Expression, Pharmacological Profile, and Functional Coupling of A2B Receptors in a Recombinant System and in Peripheral Blood Cells Using a Novel Selective Antagonist Radioligand, [3H]MRE 2029-F20. Mol. Pharmacol. 67: 2137-2147 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thiele, A. Articles by Hauschildt, S. Search for Related Content PubMed PubMed Citation Articles by Thiele, A. Articles by Hauschildt, S.